DE69739749D1 - Rekombinantes protein, das ein c-terminales fragment von msp-1 aus plasmodium enthält - Google Patents

Rekombinantes protein, das ein c-terminales fragment von msp-1 aus plasmodium enthält

Info

Publication number
DE69739749D1
DE69739749D1 DE69739749T DE69739749T DE69739749D1 DE 69739749 D1 DE69739749 D1 DE 69739749D1 DE 69739749 T DE69739749 T DE 69739749T DE 69739749 T DE69739749 T DE 69739749T DE 69739749 D1 DE69739749 D1 DE 69739749D1
Authority
DE
Germany
Prior art keywords
plasmodium
msp
recombinant protein
terminal fragment
protein containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739749T
Other languages
English (en)
Inventor
Shirley Longacre-Andre
Charles Roth
Faridabano Nato
John W Barnwell
Kamini Mendis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
New York University Medical Center
Original Assignee
Institut Pasteur de Lille
New York University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, New York University Medical Center filed Critical Institut Pasteur de Lille
Application granted granted Critical
Publication of DE69739749D1 publication Critical patent/DE69739749D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69739749T 1996-02-14 1997-02-14 Rekombinantes protein, das ein c-terminales fragment von msp-1 aus plasmodium enthält Expired - Lifetime DE69739749D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9601822A FR2744724B1 (fr) 1996-02-14 1996-02-14 Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
PCT/FR1997/000290 WO1997030158A2 (fr) 1996-02-14 1997-02-14 Proteine recombinante contenant un fragment c-terminal de msp-1 de plasmodium

Publications (1)

Publication Number Publication Date
DE69739749D1 true DE69739749D1 (de) 2010-03-18

Family

ID=9489188

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739749T Expired - Lifetime DE69739749D1 (de) 1996-02-14 1997-02-14 Rekombinantes protein, das ein c-terminales fragment von msp-1 aus plasmodium enthält

Country Status (14)

Country Link
US (5) US6958235B1 (de)
EP (2) EP0880588B1 (de)
JP (1) JP2000516083A (de)
KR (1) KR20000065266A (de)
CN (2) CN1276975C (de)
AT (1) ATE456658T1 (de)
AU (1) AU1884197A (de)
CA (1) CA2241802A1 (de)
DE (1) DE69739749D1 (de)
DK (1) DK0880588T3 (de)
ES (1) ES2338832T3 (de)
FR (1) FR2744724B1 (de)
PT (1) PT880588E (de)
WO (1) WO1997030158A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1808443A1 (de) * 2006-01-13 2007-07-18 Institut Pasteur Gereinigtes Polypeptid beinhaltend oder bestehend aus einem C-terminalen MSP1 Antigen von Plasmodium falciparum das eine Glycosylphosphatidylinositol-Gruppe (GPI) trägt
US8188213B2 (en) 1996-02-14 2012-05-29 Institut Pasteur Purified polypeptide comprising or consisting of a C-terminus MSP1 antigen from Plasmodium falciparum carrying a Glycosyl-phosphatidyl-inositol group (GPI)
FR2744724B1 (fr) * 1996-02-14 2002-08-02 Pasteur Institut Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
AP1678A (en) 1997-10-20 2006-11-27 Gtc Biotherapeutics Inc Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
CN1372568A (zh) * 1999-04-20 2002-10-02 医疗研究局 疫苗
WO2001034188A1 (en) 1999-11-12 2001-05-17 University Of Hawaii Malaria vaccine
US20030100106A1 (en) * 2000-02-08 2003-05-29 Chang Sandra P. Baculovirus produced Plasmodium falciparum vaccine
AR027370A1 (es) * 2000-02-17 2003-03-26 Lg Chemical Ltd Inmunoensayo y reactivo de diagnostico para malaria, y correspondientes metodos de preparacion, vectores de expresion y transformantes
KR100373918B1 (ko) * 2000-02-17 2003-02-26 주식회사 엘지생명과학 말라리아의 효소 면역학적 측정방법 및 이에 사용되는진단시약
KR100427513B1 (ko) * 2000-02-17 2004-04-30 주식회사 엘지생명과학 말라리아 특이 면역글로블린 엠의 검출에 의한 말라리아의면역학적 측정방법, 진단시약 및 진단방법
CN1176945C (zh) * 2001-02-01 2004-11-24 中国人民解放军第二军医大学 疟原虫融合抗原及其制法和用途
DK1350839T3 (da) 2002-04-05 2010-07-12 Pasteur Institut Identificering af de virulensassocierede regioner RD1 og RD5, hvilket muliggør udvikling af forbedrede vacciner af M. bovis BCG og M. microti
AU2004263387A1 (en) * 2003-08-12 2005-02-17 Avidis Sa Product comprising a C4bp core protein and a monomeric antigen, and its use
ATE448307T1 (de) * 2003-10-24 2009-11-15 Pasteur Institut Msp-3-ähnliche genfamilie
EP1529536A1 (de) * 2003-11-05 2005-05-11 Institut Pasteur Immunogene Verbindung mit verbesserter Immunostimulatorischer Kapazität
US20100119539A1 (en) * 2006-11-14 2010-05-13 Centro Internacional De Vacunas Vaccine against malaria, based on the 200l subuniti of plasmodium vivax msp1 protein
AU2009297127A1 (en) * 2008-09-24 2010-04-01 The Government Of The United States, As Represented By The Secretary Of The Army Malaria vaccine
CN102264381B (zh) * 2008-10-01 2014-07-09 美国政府(由卫生和人类服务部的部长所代表) 提供对疟原虫的长效免疫应答的用于疟疾的多组分疫苗
CN101921337B (zh) * 2010-07-21 2013-05-08 上海市疾病预防控制中心 间日疟原虫乳酸脱氢酶抗体、相关制备方法、杂交瘤细胞株和应用
CN103965327B (zh) * 2013-01-29 2016-08-10 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
WO2015055772A1 (en) 2013-10-16 2015-04-23 Shirley Longacre Combination of plasmodium merozoite surface proteins msp4 and 1 and uses thereof
WO2015056244A1 (pt) * 2013-10-18 2015-04-23 Universidade Federal De Minas Gerais - Ufmg Kit e método imunodiagnóstico para detecção de anemia em decorrência de malária vivax, peptídeos sintéticos e usos
BR112019012843A2 (pt) * 2016-12-23 2019-12-17 The Walter And Eliza Hall Institute Of Medical Research teste de diagnóstico, e, aparelho, sistema e método para o diagnóstico de p. vivax ou p. ovale.
JP7134461B2 (ja) * 2018-03-23 2022-09-12 国立大学法人金沢大学 マラリア治療剤、マラリア予防剤及び抗マラリア自然免疫賦活剤
CN109825514A (zh) * 2019-01-24 2019-05-31 华中农业大学 田鼠巴贝斯虫gpi10基因及其编码的蛋白和应用
CN111978413B (zh) * 2020-08-21 2022-04-15 江南大学 一种体外抑制食蟹猴疟原虫生长的抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3280028D1 (en) * 1981-05-21 1989-12-28 Wellcome Found Protozoal antigen
IL74409A (en) * 1984-02-22 1994-08-26 Wellcome Found Cloning of the p195 gene of p. falciparum and fragments thereof
US4937016A (en) * 1989-02-01 1990-06-26 Dai-Ichi Kogyo Seiyaku Co., Ltd. Copper conductor composition
FR2645877B1 (fr) * 1989-04-12 1991-07-05 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un, ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum au niveau du stade sporozoite et dans les hepatocytes
US5756101A (en) * 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
GB9203821D0 (en) * 1992-02-22 1992-04-08 Medical Res Council Improvements in or relating to malaria vaccine
EP0621337A1 (de) * 1993-01-25 1994-10-26 American Cyanamid Company Insektentoxin-AaIT-kodierende codonoptimierte DNA-Sequenz
NZ308772A (en) * 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
FR2744724B1 (fr) * 1996-02-14 2002-08-02 Pasteur Institut Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques

Also Published As

Publication number Publication date
WO1997030158A9 (fr) 1999-06-24
FR2744724A1 (fr) 1997-08-14
JP2000516083A (ja) 2000-12-05
US20020076403A1 (en) 2002-06-20
CN1276975C (zh) 2006-09-27
DK0880588T3 (da) 2010-05-17
CN1222936A (zh) 1999-07-14
FR2744724B1 (fr) 2002-08-02
US7696308B2 (en) 2010-04-13
CN101230104A (zh) 2008-07-30
KR20000065266A (ko) 2000-11-06
ATE456658T1 (de) 2010-02-15
US20070036818A1 (en) 2007-02-15
EP0880588A2 (de) 1998-12-02
US20060018932A1 (en) 2006-01-26
WO1997030158A3 (fr) 1997-10-23
AU1884197A (en) 1997-09-02
EP2194132A1 (de) 2010-06-09
US6958235B1 (en) 2005-10-25
EP0880588B1 (de) 2010-01-27
ES2338832T3 (es) 2010-05-12
CA2241802A1 (fr) 1997-08-21
PT880588E (pt) 2010-03-22
WO1997030158A2 (fr) 1997-08-21
US20100291133A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
DE69739749D1 (de) Rekombinantes protein, das ein c-terminales fragment von msp-1 aus plasmodium enthält
Sinigaglia et al. Epitopes recognized by human T lymphocytes on malaria circumsporozoite protein
EP1264890A3 (de) Plasmodium vivax Blutphaseantigene, dagegen gerichtete Antikörper und diagnostische Verfahren
ATE263243T1 (de) Schützende antikörper induzierende antigene aus plasmodium falciparum
Nudelman et al. Dual action of anti-sporozoite antibodies in vitro.
DE69434221D1 (de) Bindungs domänen von plasmodium vivax und plasmodium falciparum erythrozyten-bindenden proteinen
DE3586316D1 (de) Beschirmendes peptidantigen uebereinstimmend mit plasmodium-falciparum-circumsporozoitprotein.
Krettli et al. Malaria: a sporozoite runs through it
US4915942A (en) Cross-reactive and protective epitopes of CS
Cochrane et al. A circumsporozoite-like protein is present in micronemes of mature blood stages of malaria parasites
WO1997030159A3 (fr) Proteine recombinante contenant un fragment c-terminal de msp-1 tde plasmodium
Vergara et al. Conserved group-specific epitopes of the circumsporozoite proteins revealed by antibodies to synthetic peptides.
Vergara et al. Multiple non-repeated epitopes on the circumsporozoite protein of Plasmodium knowlesi
DK36988D0 (da) Ekspression af p.falciparum-circumsporozoitprotein af gaer
ATE214097T1 (de) Die ansteckung blockierende malariaimpfstoffe
IT1198233B (it) Metodo per la determinazione di anticorpi antisporozoita di p. falciparum nel sangue umano
ATE123302T1 (de) Rhoptry-membran-antigen von -i(plasmodium falciparum).
US5178861A (en) Cross-reactive and protective epitopes of circumsporozoite proteins
SE8803062D0 (sv) Sequential polypeptides endowed with immunological activity
ATE110741T1 (de) Synthetische peptide, die immunologische aktivität zeigen, benutzbar, um eine impfung gegen malaria vorzubereiten.
Mitchell What the papers say: Short odds for malaria vaccines
SE8702698L (sv) Polypeptid, anvendbar for framstellning av antimalariavacciner och diagnostest for pavisande av malariasjukdomar
Spencer Monoclonal antibodies binding to malarial merozoite surface protein 1 protect in vivo against Plasmodium yoelii infection.

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAELTE,

8364 No opposition during term of opposition